FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Bile Duct Neoplasms
/ diagnosis
Biomarkers, Tumor
Cholangiocarcinoma
/ diagnosis
Cisplatin
/ administration & dosage
Clinical Protocols
Deoxycytidine
/ administration & dosage
Female
Gene Rearrangement
Humans
Male
Molecular Targeted Therapy
Morpholines
/ administration & dosage
Mutation
Pyrimidines
/ administration & dosage
Pyrroles
/ administration & dosage
Receptor, Fibroblast Growth Factor, Type 2
/ genetics
Research Design
Treatment Outcome
Gemcitabine
FGFR
INCB054828
cholangiocarcinoma
pemigatinib
Journal
Future oncology (London, England)
ISSN: 1744-8301
Titre abrégé: Future Oncol
Pays: England
ID NLM: 101256629
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
pubmed:
18
7
2020
medline:
15
7
2021
entrez:
18
7
2020
Statut:
ppublish
Résumé
FGFR2 rearrangements resulting in dysregulated signaling are drivers of cholangiocarcinoma (CCA) tumorigenesis, and occur almost exclusively in intrahepatic CCA. Pemigatinib, a selective, potent, oral inhibitor of FGFR1-3, has demonstrated efficacy and safety in a Phase II study of patients with previously treated locally advanced/metastatic CCA harboring
Identifiants
pubmed: 32677452
doi: 10.2217/fon-2020-0429
pmc: PMC9892961
doi:
Substances chimiques
Biomarkers, Tumor
0
Morpholines
0
Pyrimidines
0
Pyrroles
0
Deoxycytidine
0W860991D6
FGFR2 protein, human
EC 2.7.10.1
Receptor, Fibroblast Growth Factor, Type 2
EC 2.7.10.1
Cisplatin
Q20Q21Q62J
pemigatinib
Y6BX7BL23K
Gemcitabine
0
Banques de données
ClinicalTrials.gov
['NCT03656536']
Types de publication
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
2385-2399Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Références
Nat Rev Gastroenterol Hepatol. 2016 May;13(5):261-80
pubmed: 27095655
BMC Cancer. 2016 Feb 24;16:153
pubmed: 26912134
Gut Liver. 2017 Jan 15;11(1):13-26
pubmed: 27928095
Eur J Cancer. 2014 Dec;50(18):3125-35
pubmed: 25446376
Lancet Oncol. 2015 Aug;16(8):967-78
pubmed: 26179201
JHEP Rep. 2019 Jul 10;1(4):297-311
pubmed: 32039381
JAMA Oncol. 2020 Jan 01;6(1):51-59
pubmed: 31670746
Lancet Oncol. 2020 May;21(5):671-684
pubmed: 32203698
Cancer. 2020 Jun 1;126(11):2666-2678
pubmed: 32129902
Lancet Oncol. 2012 Feb;13(2):181-8
pubmed: 22192731
Dig Liver Dis. 2019 Feb;51(2):318-320
pubmed: 30581069
Am J Surg. 2020 Jan;219(1):175-180
pubmed: 30797594
J Hepatol. 2019 Jul;71(1):104-114
pubmed: 30910538
Cancer. 2017 Jun 1;123(11):1979-1988
pubmed: 28192597
Lancet Oncol. 2020 Jan;21(1):e29-e41
pubmed: 31908303
JAMA Oncol. 2020 Jan 01;6(1):60-67
pubmed: 31670750
PLoS One. 2020 Apr 21;15(4):e0231877
pubmed: 32315352
Eur J Cancer. 2018 Mar;92:11-19
pubmed: 29413685
Nat Rev Cancer. 2017 May;17(5):318-332
pubmed: 28303906
J Natl Compr Canc Netw. 2018 Apr;16(4):370-376
pubmed: 29632056
J Clin Oncol. 2018 Jan 20;36(3):276-282
pubmed: 29182496
JCO Precis Oncol. 2017;2017:
pubmed: 29850653
Ann Hepatol. 2017 Jan-Feb 2017;16(1):133-139
pubmed: 28051802
BMC Cancer. 2019 Jan 11;19(1):55
pubmed: 30634942
Liver Int. 2019 May;39 Suppl 1:143-155
pubmed: 30843343
Invest New Drugs. 2012 Aug;30(4):1646-51
pubmed: 21748296
Oncotarget. 2017 Sep 15;8(60):101165-101174
pubmed: 29254154
J Clin Oncol. 2020 Jan 1;38(1):1-10
pubmed: 31682550
Ann Oncol. 2015 Mar;26(3):542-7
pubmed: 25538178
J Natl Cancer Inst. 2020 Feb 1;112(2):200-210
pubmed: 31077311
Lancet Oncol. 2014 Jul;15(8):819-28
pubmed: 24852116
JCO Precis Oncol. 2018 Nov;2:1-12
pubmed: 35135097
Cancer. 2016 Dec 15;122(24):3838-3847
pubmed: 27622582
Cell Rep. 2017 Mar 14;18(11):2780-2794
pubmed: 28297679
Clin Cancer Res. 2018 Sep 1;24(17):4154-4161
pubmed: 29848569
World J Clin Cases. 2019 Jul 26;7(14):1732-1752
pubmed: 31417920
PLoS One. 2014 Dec 23;9(12):e115383
pubmed: 25536104
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404